Mark Kindy to Amyloid Precursor Protein Secretases
This is a "connection" page, showing publications Mark Kindy has written about Amyloid Precursor Protein Secretases.
Connection Strength
1.176
-
The cysteine protease inhibitor, E64d, reduces brain amyloid-? and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, ?-secretase activity. J Alzheimers Dis. 2011; 26(2):387-408.
Score: 0.347
-
Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics. Biol Chem. 2007 Sep; 388(9):979-83.
Score: 0.275
-
Control of ?-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-?/? and Nuclear Factor ?-B. Curr Alzheimer Res. 2021; 18(12):941-955.
Score: 0.173
-
Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A?PP containing the wild-type ?-secretase site sequence. J Alzheimers Dis. 2012; 29(4):827-40.
Score: 0.093
-
Targets for AD treatment: conflicting messages from ?-secretase inhibitors. J Neurochem. 2011 May; 117(3):359-74.
Score: 0.088
-
Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem. 2010 Aug; 391(8):861-72.
Score: 0.084
-
Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem. 2008 Mar 21; 283(12):7745-53.
Score: 0.071
-
Brain pyroglutamate amyloid-? is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis. 2014; 41(1):129-49.
Score: 0.027
-
High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem. 2008 Jul; 106(1):475-85.
Score: 0.018